India, May 20 -- Tiziana Life Sciences (TLSA), a biotechnology company, on Tuesday released positive clinical data from the ongoing expanded access program for intranasal Foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS).
Foralumab, a human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally and is being advanced in treating progressive forms of multiple sclerosis. In 2024 intranasal foralumab was granted a breakthrough designation from the FDA.
Results from the expanded access program were updated from March 2025. The study dosed 14 patients of na-SPMS and observed the effects over 6 months. Data suggests a stabilization of disability, as measured on the expande...